Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.88 Analyst target: $9.20 Upside: 137.11%
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
See the full interactive analysis & chart →Informational only — not investment advice.